Application 091232
- Type
- ANDA
- Sponsor
- XIROMED
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | TRI-LO-ESTARYLLA | ETHINYL ESTRADIOL; NORGESTIMATE | TABLET;ORAL-28 | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091232-001 | TRI-LO-ESTARYLLA | ETHINYL ESTRADIOL; NORGESTIMATE | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | TABLET / ORAL-28 | AB | 2015-06-29 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A091232-001 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A091232-001 | TRI-LO-ESTARYLLA | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | TABLET / ORAL-28 | AB | 2015-06-29 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A091232-001 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tri-Lo- Estarylla | NORGESTIMATE AND ETHINYL ESTRADIOL | Bryant Ranch Prepack | 90f7ab24-7839-4408-9a74-07bb6a79eacc | 2024-05-21 | Boxed warning, Warnings, Adverse reactions | 091232 ANDA091232 63629-2351 |
| Norgestimate and Ethinyl Estradiol | NORGESTIMATE AND ETHINYL ESTRADIOL | AvKARE | a3ce752d-58df-363d-e053-2a95a90a5411 | 2024-01-10 | Boxed warning, Warnings, Adverse reactions | 091232 ANDA091232 42291-565 |
| Tri-Lo- Estarylla | NORGESTIMATE AND ETHINYL ESTRADIOL | Xiromed, LLC. | 8381db98-f9b2-e894-c07e-5d49f10e4eea | 2023-12-21 | Boxed warning, Warnings, Adverse reactions | 091232 ANDA091232 70700-120 |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0781-4062 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Sandoz Inc | ANDA | Current |
| 42291-565 | Norgestimate and Ethinyl Estradiol | norgestimate and ethinyl estradiol | AvKARE | ANDA | Current |
| 42291-565 | Norgestimate and Ethinyl Estradiol | norgestimate and ethinyl estradiol | AvKARE | ANDA | Current |
| 63629-2351 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Bryant Ranch Prepack | ANDA | Current |
| 63629-2351 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Bryant Ranch Prepack | ANDA | Current |
| 63629-2351 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Bryant Ranch Prepack | ANDA | Current |
| 70700-120 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Xiromed, LLC. | ANDA | Current |
| 70700-120 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Xiromed, LLC. | ANDA | Current |
| 70700-120 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Xiromed, LLC. | ANDA | Current |
| 70700-120 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Xiromed, LLC. | ANDA | Current |
| 70700-120 | Tri-Lo- Estarylla | norgestimate and ethinyl estradiol | Xiromed, LLC. | ANDA | Current |